2021-12-31-accounts - Society For Endocrinology

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Memorandum and Articles of	Memorandum and Articles of	Memorandum and Articles of	Memorandum and Articles of	Memorandum and Articles of	Memorandum and Articles of	Association.
The administrative Information						required to be given is	as		follows:
Charity Registration				No:		266813					Registered			with the Charity	Commission		for
											England		and Wales
Company	Registration				No:	349408
Principal Offic:	and Registered					Starling House 1600Bristol Parkway		North
						Bristol BS348YU
Council of		Management:
Professor		R	V Thakker			(President)
Professor		E	Device			(General Secretary)			Resigned		09/11/21
Professor		R	Andrew			(General Secretary)			Appointed		09/11/21
Professor		M	Gurnell			(Treasurer)
Professor		J H D Bassett				(Programme Secretary) Resigned						09/11/21
Professor		R	K Sample			(Programme Secretary) Appointed						09/11/21
Professor		K	Boelaert
Dr A M Brooke
Professor		S	Forbes
Dr M Freel
Dr T M Keamey
Professor		M	J Korbonits			Appointed 09/11/21
Professor		G	G Lavery
Dr D A Ress
Professor		R	M Reynolds
Senior Staff:
I Russell						(Chief Executive &	Company			Secretary)
D Mills						(Finance Director)
L Udakis						(Director of Membership			Engagement)
M Hook						(HR & Performance	Director)
R Cropley						(Operations Director)
K Sargent						(Deputy Managing	Director, Bioscientiiica)
						No staff are registered			as directors			ofthe		Society for Endocrinology		at
						Companies House.	The term			'director'			is	used for internal	purposes	only.
Independent			Auditor:			Haysmacintyre LLP
						10Queen Street Place
						London
						EC4R 1AG

			Applications	Awarded	Value (8)
Conference grants			124	110	50,397
SfE BESfree places			33	29	9,326
Early career grants			42	21	183,847
Summer studentships			14	7	20,940
Patient support grants			7	7	3,394
Public engagement	grants		3	3	2,670
Undergraduate achievement		awards	2	6	1,800
Practical skills grants			9	3	5,958
Equipment grants			6	1	9,700
Clinical department	grants		14	5	4,400
Meeting Support Grants			5	5	39,825
Other grants			0	1	4,950
Total			259	198	337,207

Journal		2017	2018	2019	2020	2021
Journal of	Endocrinology	4.706	4.012	4.381	4.041	4.286
Journal of	Molecular Endocrinology	3.577	3.297	3.744	3.562	5.098
Endocrine-Related Cancer		5.267	5.331	4.774	4.800	5.678
Endocnne	Connections	2.541	3.041	2.474	2.592	3.335

									Yearended
				Year ended		31 December 2021			31 December 2020
				Unrestricted Funds	Restricted Funds		Total Funds		Total Funds
			Note	f000		9000		6000	f000
income from:
Charitable activities				2,504		292		2,796	2,146
Other trading activities				3,194				3,194	3,105
Investments				86				93	84
Other				130				130	145
Total				5,914		299		6,213	5,480
Expenditure on:
Raising funds				3,346				3,346	3,424
Charitable activities				2,394		75		2,469	1,937
Other				21		2		23	21
Total				5,761		77		5,838	5,382
Net (losses)/gains	on investments			400		22		422	58
Net (expenditure)/Income				553		244		797	156
Transfers between		funds		20		(20)
Net Movement in	funds			573		224		797	156
Reconciliation of	funds:
Total funds brought		forward		5,599		331		5,930	5,774
Total funds canied		forward		6,172		555		6,727	5,930

						2021	2021	2020	2020
						Group	Company	Group	Company
					Note	f000	f000	f000	f000
Fixed Assets:
Intangible assets					12	1	1	21	21
Tangible assets					13	1,805	1,805	1,881	1,881
Investments					14	4,660	4,660	4,114	4,114
Investment in Bioscientifica				Limited
Total fixed assets						6,466	6,467	6,016	6,017
Current Assets
Debtors					15	1,751	356	2,055	498
Cash at bank and	in	hand			16	2,430	1,369	2,147	996
Total current assets						4,181	1,725	4,202	1,494
Liabilities:
Creditors: Amounts within one year		falling		due	17	3,168	762	3,507	849
Net current assets						1,013	963	695	645
Total assets less current			liabilities			7,479	7,430	6,711	6,662
Long term loans					18	752	752	781	781
Net assets						6,727	6,678	5,930	5,881
The funds ofthe	charity:
Restricted income	funds				19	555	555	331	331
Unrestricted funds					20	6,172	6, 123	5,599	5,550
Total charity funds						6,727	6,678	5,930	5,881

			Year	Year
			ended	ended
			31/12/21	31/12/20
		Note	8000	8000
Cash flows from operating activities:
Net cash provided by /(used in) operating	activities		344	131
Cash flows from investing activities:
Dividends and interest			93	84
Purchase of property, plant and equipment			(1)	(5)
Proceeds from sale of investments			1,062	1,126
Purchase of investments			(1,175)	(1,305)
Movement In cash awaitIng investment			(11)	(62)
Net cash provided by investing activities			(32)	(162)
Sale of property asset held for resale
Noncash movement in Long Term Loans			(29)	(31)
Change in cash and cash equivalents in the period	reporting		283	(62)
Cash and cash equivalents at the beginning reporting period	ofthe		2,147	2,209
Cash and cash equivalents at the end of the reporting period			2,430	2,147
a) Reconciliation of net Income to net cash flow from operating
activities
Net (expenditure)/income for the year (as financial activities)	per the statement	of	797	156
AdJustments for:
Depreciation and amortisation charges			97	118
Gains on investments			(422)	(58)
Dividends and interest from investments			(93)	(84)
Decrease/(Increase) in debtors			304	(131)
(Decrease) /Increase in creditors			(339)	130
Net cash provided by operating activities			344	131
b) Analysis ofcash and cash equivalents
Cash in hand			535	756
Notice deposits (less than 3 months)			1,895	1,391
Total cash and cash equivalents			2,430	2,147

	January	Cash	Other non-	Other non-	31 December
	2021	Flows	cash	changes	2021
	f000	f000		f000	f000
Cash	2,147	283			2,430
Borrowings
Debt due within one year	(37)	33		(29)	(33)
Debt due alter one year	(781)			29	(752)
	(818)	33			(785)
	1,329	316			1,645

n analy	sis of Group income by geographical loc	ation Is given below:
		Yearto	Year to
		31/12/21	31/12/20
		0/	0/
United	Kingdom	28	21
Europe		42	42
North America		10	9
Rest of	the Wodd	20	28
		100	100

Summary profit and loss account	Summary profit and loss account	Year to 31/12/21	Year to 31/12/20
		6000	f000
Turnover		5,136	5,066
Cost ofsales		(2,808)	(2,772)
Gross profit		2,328	2,294
Administration		(1,105)	(1,185)
Operating profit		1,223	1,109
Interest receivable	and similar income	26	32
Profit on ordinary	activities	1,249	1,141
Gift Aid		(1,249)	(1,324)
Profit before taxation			(183)
Taxation
Retained in subsidiary			(183)
Total assets and	liabilities of	Yearto	Year to
the subsidiary were:		31/12/21	31/12/20
		f000	f000
Fixed assets
Current assets		2,456	2,709
Creditors: amounts	falling due	(2,406)	(2,659)
Total net assets		50	50
Aggregate share capital		50	50

		Unrestricted	Restricted	Year to	Year to
		funds	funds	31/12/21	31/12/20
		f000	f000	6000	6000
Publications		1,697		1,697	1,776
Society events and	conferences (see below)	560		560	199
Other membership subscrlptions)	services (including	235		235	171
Grants received		12	292	304
		2,504	292	2,796	2,146

Income	from Socie	ty events a	nd
				Year to	Year to
				31/12/21	31/12/20
				6000	f000
The Society annual		meeting		503	173
Training	and other	registration	fees	57	26
				560	199

5) Inc	ome fro	m ot	her trading activiti	es
				Unrestricted	Restricted	Year to	Year to
				funds	funds	31/12/21	31/12/20
				FOOO	f000	6000	6000
Trading	income	from	subsidiary	3,194		3,194	3,105

6) Other	income
		Unrestricted	Restricted	Year to	Year to
		funds	funds	31/12/21	31/12/20
		FOOO	FOOO	6000	FOOO
Royalties	received	130		130	145

					Unrestricted	Restricted	Year to	Year to
					funds	funds	31/12/21	31/12/20
					f000	f000	f000	6000
Trading	costs	of	subsidiary	company	3,346		3,346	3,424

8) Expenditu	re	o	n charita	ble activitie	s
					Direct	Grants	Support	Year to	Year to
					costs	paid	costs	31/12/21	31/12/20
							(note 9)
					6000	6000	OOOO	f000	f000
Publications					567			567	533
Society events	and		conferences		385		248	633	78
Other membership subscriptions paid)			services	(Including	503	366	325	1,194	1,320
Society research		projects			75			75
					1,530	366	573	2,469	1,937
2020					Direct costs	Grants paid	Support costs	Yearto 31/12/20
							(note 9)
					8000	8000	6000	6000
Publications					533			533
Society events	and		conferences		34			78
Other membership subscrlptlons paid)			services	(including	453	279	588	1,320
Society research		projects
					1,026	279	632	1,937

Grants paid are made up as	follows:
				Grants	Staff and	Year to	Year to
			No	paid 6000	other f000	31/12/21 6000	31/12/20 f000
Grants payable to individuals
Travel grants and grants for meetings and conferences	attendance	at	139	60	4
Summer studentships			7	21		22	29
Early career grants			21	184		188	184
Total grants payable toindividuals			167	265	9	274	213
Grants paid toinstitutions:
Patient support grants							17
Public engagement grants							1
Undergraduate achievement	award						5
Regional clinical cases grants
Other grants			15	64	20	84	63
Total grants paid toinstitutions:			31	72	20	92	86
Total grants paid			198	337	29	366	299
Adjustment for Endocrine Academy 2020
Conference grants awarded	In 2019but	not					(20)
paid due to COVID-19
			198	337	29	366	279

							Grants	Staff and	Year to
2020							paid	other costs	31/12/20
						No	f000	FOOO	6000
Grants payable toindividuals
Travel grants		and grants for		attendance	at meetings
and conferences
Summer studentships						11	28	1	29
Early career		grants				19	179	5	184
Total grants		payable	toindividuals			30	207	6	213
Grants paid		toinstitutions:
Patient support grants						8	17		17
Public engagement			grants			1	1		1
Undergraduate achievement				award		18	5		5
Other grants						9	59		63
Total grants		paid to	institutions:			36	82	4	86
Total grants		paid				66	289	10	299
Adjustment	for Endocrine Academy 2020
Conference		grants awarded		in 2019but	not paid due	(31)	(23)	3	(20)
to Covid
						35	266	13	279

Support co as follows:	s	ts are all directly attributable to charitable	activities as shown in note 8 and are	made up
			Year to	Year to
			31/12/21	31/12/20
			6000	6000
Governance			50	54
Finance and		administration	280	290
Information		technology	106	110
Marketing	and communications		32	32
Human resources			122	83
Executive			170	63
VAT Refund			(187)
Total			573	632

This is state	d after ch	arging	:
										Year to		Year to
										31/12/21		31/12/20
										f000		f000
Depreciation	and amortisation									98		117
Auditor's remuneration:
Group audit	services									21		18
Accountancy	and other services									4		9
11)Staff costs
Staff costs during the		year	amounted		to:
										Year to		Year to
										31/12/21f		31/12/20f
Salaries										2,564,497		2,478,828
Social	security costs									254,022		251,651
Other pension costs										287,853		274,481
										3,106,372		3,004,960
The number	of employees		whose	remuneration			was within		the	bands stated was as follows:
										Yearto		Year to
										31/12/21		31/12/20
										Number		Number
f60,001 - F70,000
f70,001 - f80,000
F120,001 - F130,000
The average	number	of full-time		equivalent		employees		analysed		by function was:
										Year	to	Year to
										31/12/21		31/12/20
										Number		Number
Charitable	activities										56	59
Administration											22	23
											78	82

	Group and Company	Group and Company
	Office software	2020
	f000	f000
Cost:
01-Jan-21	255	253
Additions		2
31-Dec-21	255	255
Amortlsatlon
01-Jan-21	234	199
Charge for the year	20	35
31-Dec-21	254	234
Net Book Value
31-Dec-21		21
13)Tangible assets
Group and Company

13)Tangible assets Group and Company
	Freehold	land	Fixtures	Office	Company	Development	Group
	and buildings		and	equipment	total	costs	total
			fittings
		f000	f000	f000	f000	f000	f000
Cost:
1 January 2021		1,767	284	444	2,495	37	2,532
Additions				1	1		1
Disposals
31 December 2021		1,767	264	445	2,496	37	2,533
Depreciation
1 January 2021		101	123	390	614	37	651
Charge for the year		34	27	16	77		77
Eliminated on
disposals
31 December 2021		135	150	406	691	37	728
Net Book Value
31 December 2021		1,632		39	1,805		1,805
31 December 2020		1,666	161	54	1,881		1,881

14) Listed	In	vestments
				Group and	Company
				2021	2020
				6000	6000
Market value		at 1 January	2021:	3,980	3,742
Additions				1,175	1,305
Disposals				(1,062)	(1,125)
Movement	in	cash awaiting	investment
Net unrealised		investment	gains	422	58
Market value		at 31 December 2021		4,515	3,980
				Group and	Company
				2021	2020
				6000	6000
The market	value at 31 December 2021 comprises:
Listed investments				4,515	3,980
Cash awaiting		investment		145	134
				4,660	4,114

15) Debto	rs
			2021		2020
			Group	Company	Group	Company
			6000	6000	6000	f000
Trade and	other debtors		1,175	129	1,514	280
Prepayments		and accrued income	570	227	453	218
Derivative	Asset		6		88
			1,751	356	2,055	498

16)Cash at bank and ln hand
		2021	2020
	Group	Company	Group	Company
	FOOO	f000	6000	f000
Bank current accounts	533	22	753	22
Monies held on deposit	1,895	1,347	1,391	974
Petty cash	2		3
	2,430	1,369	2,147	996

17) Cre	ditors:	amo	unts f	allin	g due within one	year	year
						2021			2020
						Group	Company	Group	Company
						f000	8000	6000	6000
Bank Loans						33	33	37	37
Trade creditors						242	150	255	29
Amounts	due to	subsidiary					11		39
Clients'	accounts					114		73
Deferred	income					1,247	107	1,225	108
Other taxes and		social security				82	82	90	90
Other creditors		and	accruals			1,450	379	1,827	546
						3,168	762	3,507	849
							2021	2020
						Group	Company	Group	Company
						8000	8000	8000	f000
Deferred	income at		1 January		2021	1,225	108	1,256	122
Resources deferred			in the	year		1,247	107	1,225	108
Amounts	taken	to income		in the		(1,225)	(108)	(1,256)	(122)
Deferred	income at		31 December 2021			1,247	107	1,225	108

					and Company	and Company
					2021	2020
					f000	FOOO
Loan	repayment	year	1		33	37
Loan	repayment	years		2-5	151	147
Loan	repayment	years		5+	601	634
					785	818

2021	Balance at	Movement	in resources	Transfer	Investment	Balance at 31
Group and	1 January	Income	Expenditure	between	gains/	December
company	2021			funds	(losses)	2021
	FOOO	f000	f000	f000	f000	f000
CaHASE Fund
Anti-Thyroid
Drug Study
ACC Service
Improvement			(4)
Marjorie Robinson Fund	327		(3)	(20)	22	333
Obesity Database			(69)			185
Endocrine Nurse
Network						10
Besins Service		20				20
Improvement
	331	299	(77)	(20)	22	555
2020	Balance at	Movement	in resources	Transfer	Investment	Balance at 31
Group and	1 January	Income	Expenditure	between	gains/	December
company	2020			funds	(losses)	2020
	f000	f000	f000	FOOO	f000	f000
CaHASE Fund			(2)
Anti-Thyroid Drug Study			(4)
Marjorie Robinson Fund	359		(2)	(20)	(18)	327
	370	7	(8)	(20)	(18)	331

2021		Balance	Movement	Movement	in	Transfer	Investment	Balance at
		at 1	resources			between	gains/(losses)	31
		January	Income	Expenditure		funds		December
		2021						2021
		f000	f000		f000	f000	f000	f000
Company		5,550	1,023		(1,848)	998	400	6,123
Bioscientifica Limited		49	4,891		(3,913)	(978)		49
Group tot aI		5,599	5,914		(5,761)	20	400	6,172
Bioscientifica	Limited	profits off1,249k were		transferred to the		Company	as gift aid (2020	f1,141k).
2020		Balance	Movement		in	Transfer	Investment	Balance at
		at 1	resources			between	gatns/(losses)	31
		January	Income	Expenditure		funds		December
		2020						2020
		f000	f000		f000	f000	f000	f000
Company		5,172	589		(1,416)	1,129	76	5,550
Bioscientifica Limited		232	4,883		(3,957)	(1,109)		49
Group total		5,404	5,472		(5,373)	20	76	5,599

21)Analysis of Group and Company	21)Analysis of Group and Company	net assets between funds
		Unrestricted funds	Restricted Funds	2021	2020
		FOOO	E'000	FOOO	6000
Intangible fixed assets		1		1	21
Tangible fixed assets		1,805		1,805	1,881
Listed Investments		4,284	376	4,660	4,114
Debtors		1,572	179	1,751	2,055
Cash at bank and	in hand	2,430		2,430	2,147
Creditors		(3,168)		(3,168)	(3,507)
Long term loans		(752)		(752)	(781)
		6,172	555	6,727	5,930
Company		Unrestricted funds	Restricted Funds	2021	2020
		f000	FOOO	FOOO	f000
Fixed assets		1,806		1,806	1,902
Listed Investments		4,284	376	4,660	4,114
Investment in Subsidiary				1	1
Debtors and Cash		1,546	179	1,725	1,494
Creditors		(762)		(762)	(849)
Long term loans		(752)		(752)	(781)
		6,123	555	6,678	5,881
Group 2020		Unrestricted funds	Restricted Funds	2020
		8000	6000	6000
Fixed assets		1,902		1,902
Listed Investments		3,758	356	4,114
Debtors and Cash		4,227	(25)	4,202
Creditors		(3,507)		(3,507)
Long term loans		(781)		(781)
		5,599	331	5,930
Company 2020		Unrestricted funds	Restricted Funds	2020
		ZOOO	8000	FOOO
Fixed assets		1,902		1,902
Listed Investments		3,758	356	4,114
Investment in Subsidiary
Debtors and Cash		1,519	(25)	1,494
Creditors		(849)		(849)
Long term loans		(781)		(781)
		5,550	331	5,881

2) Transfer between funds
				2021	2020
During the year the following	transfers	were made between	funds:
From the Marjor/e Robinson	Fund to:
Main Fund to provide early	career research grants			20 000	20 000

					Year ended	31/12/21	Year ended	31/12/20
				Note	f000	f000	FOOO	f000
Income from activities:
Membership subscriptions					151		146
Event income					542		161
Royalties receivable					146		165
Advertising income							0
Sundry income					98		43
						937		515
Expenditure on activities:
Divisional Salaries					340		327
Publishing costs					18		20
Venue and catering costs					317		11
Bioscientiffca management			fees		260		215
Programmes, abstracts		and	handbooks		17		6
Expenses					74		26
Marketing					13		16
Other direct expenses					91		60
Grants					337		265
						1 462		946
Deficit from activities Overheads						(530)		(431)
Salaries					604		486
Other staff costs					127		99
Staff expenses					16		10
Premises costs					143		142
Insurance					23		27
Professional fees					20		19
Investment manager's	fees				21		19
Printing, postage, stationery			and		3		5
Depreciation					98		117
General tax write Off					(189)		0
Marketing					1		0
Bank and credit card charges					19		19
Sundry office expenses					30		29
Recharged					(264)		(2884
						662		684
Deficit from Main Fund		before
investment income and gains on						(1,182)		(1,115)
Investments (carried	forward)

				Year ended	31/12/21	Year ended	31/12/20
			Note	8000	8000	8000	f000
Deficit from	Main Fund before
Investment	income and gains	on			(1,182)		(1,115)
Investments	(brought forward)
Income from	listed investments			86		75
Bank deposit	interest					0
Gift aid from	Bioscientifica Limited			1,249		1,324
					1,335		1,399
(Deficit) / Surplus prior to transfers					153		284
Transfers from / (to) designated		funds			(20)		20
Surplus from	unrestricted fund before				173		304
gains on Investments
Net gains/(losses) on investments					400
Total surplus / (deficit) for the		year			573		380

						2021			2020
				Note	6000	FOOO		OOOO	E'000
Fixed Assets
Intangible assets							1		21
Tangible assets						1,805			1,881
Listed investments						4,284			3,758
Investment In Bioscientifica			Limited				1
						6,091			5,661
Current assets
Debtors and prepayments					356			498
Bloscientifica Limited					(11)			(39)
Cash at bank and		In hand			1,369			996
					1,714			1,455
Current liabilities
Income in advance					107			108
Creditors and accruals					644			538
Long term loans					751			781
Obesity database					185			165
Marjorie Robinson		Fund			(43)			(31)
CaHASE Fund					1			1
Anti Thyroid Drug		Study			3			4
ACC Service Improvement			Fund		4
Endocrine Nurse	Network		Fund		10
Besins Research	Fund				20
					1,682			1,566
Net Current Assets							32
Total assets less		cunent	liabilities			6,	123		5,550
Financed by:
Unrestricted Fund				19		6,123			5,550

					Year ended	Year ended
					31/12/21	31/12/20
			Note		f000	f000
Listed investment	Income
Interest received
Expenditure on activities:
Grants paid					20	20
Investment managers'		fees			(2)	2
					18	22
Deficit before gains /(losses)			on investment		(11)	(15)
Gains / (losses) on investments					22	(18)
Surplus for the year						(33)
Balance sheet at	31	December 2021
					2021	2020
Fixed Assets
Listed investments					376	356
Current assets
Main Fund —current		account			(43)	(31)
Net assets					333	325
Financed by:
Marjorie Robinson	Fund			18	333	325

				Year ended	Yearended
				31/12/21	31/12/20
		Note		f000	f000
Income	from activities:
Grants received
Expenditure on activities:
General	expenses
Management charge
Surplus	/ {Deficit)for the year				(2)
Balance	sheet at 31 December 2021
				2021	2020
Current	assets
Main Fund —current account
Net current assets
Financed	by:
CaHASE	Fund		18

			Year ended	Year ended
			31/12/21	31/12/20
	Note		f000	E000
Income from activities:
Grants received
Expenditure on activities:
General expenses
Management charge				(4)
				(4)
Surplus / (Deficit) for the year
Balance sheet at 31 December 2021
			2021	2020
			8000	EOOO
Current assets
Main Fund —current account
Net current assets
Financed by:
Anti Thyroid Study Fund		19

				Year ended
				31/12/21
		Note		OOOO
Income from activities:
Grants received
Expenditure on activities:
General expenses
Management charge
Surplus / (Deficit) forthe	year
Balance sheet at 31 December 2021
				2021
				f000
Current assets
Main Fund —current account
Net current assets
Financed by:
ACC Service Improvement	Fund		19

			Year ended
			31/12/21
	Note		6000
Income from activities:
Grants received			254
Expenditure on activities:
Development costs			66
Management charge			3
			69
Surplus / (Deficit) for the year			185
Balance sheet at 31 December 2021
			2021
			f000
Currentassets
Main Fund —current account			185
Net current assets			185
Financed by:
Obesity Database Project Fund		19

				Year ended
				31/12/21
		Note		f000
Income from activities:
Grants received				10
				10
Expenditure on activities:
General expenses
Management charge
Surplus / (Deficit) for the	year			10
Balance sheet at 31 December 2021
				2021
				f000
Current assets
Main Fund —current account				10
Net current assets				10
Financed by:
Endocrine Nurse Network	Fund		19	10

				Year ended
				31/12/21
		Note		f000
Income from activities:
Grants received				20
				20
Expenditure on activities:
General expenses
Management charge
Surplus / (Deficit) for the year				20
Balance sheet at 31 December 2021
				2021
				FOOO
Current assets
Main Fund —current account				20
Net current assets				20
Financed by:
Besins Service Improvement	Fund		19	20